Anti‑epidermal growth factor receptor monoclonal antibody therapy in locally advanced head and neck cancer: A systematic review of phase III clinical trials.

However, to the best of our knowledge, at present, there are no validated molecular markers for the prediction of the response to anti-EGFR therapy ( 13 ) except for the finding that in patients who had skin rash when cetuximab was added to RT showed a positive trend in survival outcomes ( 13 , 38 , 39 ).

also in 11,005 other papers